Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital's venture capital and private equity team.

Dr. Kibar received his MS and PhD, specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a BS in Electrical Engineering from Caltech and a BA in Mathematical Economics from Pomona College.

Troy Cox, former CEO of Foundation Medicine, is striving to make a difference in patients’ lives by serving on the boards of innovative growth companies in the Biotech, Genetics, Diagnostic, and Digital Health industries. As President and Chief Executive Officer, Mr. Cox led Foundation Medicine (NASDAQ: FMI) through the acquisition by Roche for $5.3 billion in 2018. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles of increasingly broad accountabilities including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. Mr. Cox received his MBA at the University of Missouri and BBA in Finance from the University of Kentucky. He is Chairman of Sophia Genetics (Series F), Vice Chairman of LetsGetChecked (Series C), Board Director at Zymeworks (NYSE: ZYME) and CM Life Sciences II as well as non-profits Massachusetts BioTechnology Council (MassBio) and Dream Foundation.

Susannah Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019 just ahead of the Company’s initial public offering. At Royalty Pharma, Ms. Gray led the Company’s efforts to maximize its financial capabilities. In her career at Royalty Pharma, she increased the debt facilities from approximately $200 million to $7 billion, and was responsible for over $20 billion in total financing. She also raised $2.0 billion equity capital for the Company.

Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a Managing Director and the Senior Analyst covering the healthcare sector for CIBC World Market’s high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University. Ms. Gray currently serves on the board of directors of Susan G. Komen and is on the board of trustees at Wesleyan University.

Brian Chow, PhD, serves as a Research Analyst for Eventide, and Principal for Eventide Ventures. Dr. Chow has research responsibilities for healthcare investments at Eventide.

Prior to joining Eventide, Dr. Chow served as Senior Associate with 5AM Ventures. His background includes work as a neuroscience researcher as well as a venture investor. Dr. Chow studied under both Nobel Laureate Dr. Ardem Patapoutian and Dr. Chenghua Gua, a 2021 Howard Hughes Medical Institute Investigator. Dr. Chow’s doctoral research focused on the biological mechanisms underlying the blood-brain barrier, with the potential to enhance drug delivery to the brain to treat neurological disorders. He published his discoveries as first author in the journals Nature and Neuron and wrote several peer-reviewed articles published in Nature Review Neuroscience and Trends in Neuroscience. During Dr. Chow’s doctoral program, he also worked at life sciences venture firm Flagship Pioneering.

Dr. Chow holds a PhD in Neuroscience from Harvard University’s Graduate School of Arts and a BS in Biology and Chemistry from the University of California San Diego.

Chidozie Ugwumba serves as Managing Partner of SymBiosis, a venture capital firm focused on investments in biotherapeutics. At SymBiosis, Mr. Ugwumba leads sourcing, due diligence, and execution of investments, and serves as an advisor to SymBiosis’ portfolio companies. He has led numerous investments in therapeutics companies in the US and Europe, across disease areas including CNS, cardiac, dermatology, GI, infectious disease, and oncology, and across modalities such as precision medicine, and cell, gene, and regenerative therapy. Prior to SymBiosis, Mr. Ugwumba led the Direct and Impact Investment Group of WIT, LLC—an investment management entity affiliated with Walton Enterprises—and worked on the Private Credit and Infrastructure teams at Partners Group, a global private investment manager. Mr. Ugwumba earned an MBA from the Johnson Graduate School of Management at Cornell University, and a BA in Political Science from Amherst College.

Stephen Zachary is a Partner and Portfolio Manager at Sands Capital and serves on the Boards of various therapeutics, diagnostics, and life sciences tools companies. Stephen received his PhD in Neuroscience from Johns Hopkins School of Medicine, and received a BA in Philosophy from Washington & Lee University. He is a member of the Kauffman Fellowship (Class 23).

Mr. Ahmed Khizer Khan is the CEO of Daman Investments, a pioneer firm in the UAE's financial services industry. Mr. Khan is a globally recognized business leader, banker and change agent with over three decades of global leadership experience. After an Honors degree in Economics from Bucknell, and an MBA from Rutgers, he spent his formative years in USA, Central Europe, UAE, and Pakistan with PWC and Citibank; before joining Barclays Global Retail and Commercial Bank as its Chief Executive, Emerging Markets, responsible for 15 countries including high-growth markets like India, UAE, Africa, Russia, Pakistan and Indonesia.

Mr. Khan served on the Barclays Board for several countries, working with the Global Chairman on formulating strategies for the emerging markets. After an impactful stint at the Islamic Corporation for the Development of the Private Sector, Jeddah, as its COO & Director Coverage, Partnerships and Syndication, across 35 countries; he became the President & Chief Executive Officer of Burj Bank Limited in Pakistan, where he turned around a small loss-making entity into the fastest growing Islamic Bank in Pakistan.

Mr. Khan, with nearly three decades of international banking industry experience, took over the reins at Daman Investments in 2016, with a mandate to re-engineer the business. Under his leadership, the company has increased footprint in new areas and won mandates for large M&A and investment banking projects. In a short span of time, he has been instrumental in achieving over 100% growth in profitability. He has led Daman Investments in conducting one of the largest leveraged buyouts within the family-owned entities in UAE. Established in 1998, Daman Investments has been actively offering investment opportunities to the institutional, high net-worth, and retail customers in UAE and beyond.

Mr. Khan is leading and managing the Gargash Group Family Office while also serving as a Board Member for Gargash Group since 2016. The Gargash Group is amongst the largest business conglomerates in UAE with more than 28 businesses across diversified industries including Automotive, Real Estate, Financial Services, F&B and several others. Currently Mr. Khan is also serving on the Board of Deem Finance LLC; a leading consumer finance business in the UAE.

Simon Faure is the Managing Director of IH International Advisors, a global private equity investment advisory business. Prior to joining IHIA in 2021, Simon spent 16 years at M&G Investment’s private equity team. Simon has over 20 years’ experience investing in private equity and over 25 years' investment experience in total. Simon has a History degree from University of Southampton..